Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Kaposi 1AIDS-related Kaposi sarcoma 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × halofuginone × Clear all
NCT00064142 2013-06-05

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled
Sarcoma

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi

NCT00027677 2012-07-24

Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡